STERIS

OverviewSuggest Edit

STERIS is a global leader in infection prevention, contamination control, surgical technologies, and more.
STERIS is the world’s pre-eminent infection prevention, decontamination, and surgical and critical care company, with a long list of first-to-market products and industry-leading service innovations and thousands of customers in more than 60 countries.
While the corporation was founded as Innovative Medical Technologies in 1985 and renamed STERIS in 1987, our history dates back to 1894 with the founding of American Sterilizer Company, a long-time, global leading innovator of sterilization products.
Today, through a series of strategic acquisitions and continual innovation of new products, STERIS holds one of the broadest portfolios of products in the industry. It stands at the forefront of efforts to prevent infection and contamination in healthcare and pharmaceutical environments, and is broadening its reach with products to meet the needs of defense and industrial markets.

TypePublic
Founded1987
HQMentor, OH, USMap
Websitesteris.com
Employee Ratings3.8More
Overall CultureC+More
View Jobs (411)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)12,000
Job Openings411
Revenue (FY, 2018)$2.6 B
Share Price (Apr 2021)$193.8
Cybersecurity ratingCMore

STERIS Office Locations

STERIS has offices in Mentor, Birmingham, Chester, Chesterfield and in 76 other locations
Mentor, OH, US (HQ)
5960 Heisley Rd
Birmingham, AL, US
3316 2nd Ave N
Chester, NY, US
23 Elizabeth Dr
Chesterfield, MO, US
515 Trade Center Blvd
Cooper City, FL, US
12229 SW 53rd St
Costa Mesa, CA, US
1011 Brioso Dr #106
Show all (99)

STERIS Financials and Metrics

STERIS Revenue

Embed Graph
View revenue for all periods
STERIS's revenue was reported to be $2.62 b in FY, 2018
USD

Revenue (Q3, 2019)

696.2m

Gross profit (Q3, 2019)

287.0m

Gross profit margin (Q3, 2019), %

41.2%

Net income (Q3, 2019)

48.4m

EBIT (Q3, 2019)

69.6m

Market capitalization (7-Apr-2021)

16.5b

Closing stock price (7-Apr-2021)

193.8

Cash (31-Dec-2018)

224.9m

EV

17.6b
STERIS's current market capitalization is $16.5 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.6b1.9b2.2b2.6b2.6b

Revenue growth, %

14%21%17%

Cost of goods sold

972.6m1.1b1.3b1.6b1.5b

Gross profit

649.6m774.3m895.5m1.0b1.1b
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

618.7m638.4m646.4m646.8m608.0m634.2m661.9m638.8m679.0m696.2m

Cost of goods sold

380.5m398.4m398.5m389.2m351.8m367.4m383.3m369.7m394.3m409.2m

Gross profit

238.2m240.0m247.9m257.6m256.1m266.8m278.6m269.1m284.7m287.0m

Gross profit Margin, %

38%38%38%40%42%42%42%42%42%41%
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

152.8m167.7m248.8m282.9m201.5m

Accounts Receivable

313.7m325.3m471.5m483.5m528.1m

Prepaid Expenses

54.3m

Inventories

37.0m35.0m59.4m197.8m205.7m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

231.4m242.4m254.4m264.9m294.8m295.6m283.8m218.5m209.9m224.9m

Accounts Receivable

440.9m439.8m441.3m443.7m455.6m449.4m472.1m481.5m491.0m509.9m

Prepaid Expenses

54.8m54.0m50.6m52.1m62.1m57.4m57.5m55.0m47.8m58.1m

Inventories

208.3m209.6m209.9m209.7m217.4m224.8m219.5m233.9m230.8m227.6m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

129.4m135.1m110.8m110.6m291.6m

Depreciation and Amortization

188.1m178.3m

Inventories

(12.8m)(5.2m)

Accounts Payable

19.4m(3.1m)5.2m6.9m563.0k
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

53.7m48.4m88.8m83.8m58.2m122.7m218.0m70.3m147.8m

Depreciation and Amortization

90.9m53.8m103.9m135.2m43.7m89.2m133.9m46.9m93.0m

Inventories

(15.5m)(19.8m)(21.7m)(27.4m)(15.8m)(19.0m)(21.6m)(34.1m)(33.0m)

Accounts Payable

(17.9m)(13.2m)(17.0m)(5.8m)(10.2m)(8.6m)(10.6m)(1.9m)(7.4m)
show all
USDFY, 2014

Financial Leverage

1.8 x
Show all financial metrics

STERIS Operating Metrics

FY, 2016

Patents (Foreign)

1.1 k

Patents (US)

390

Patents Pending

470
Show all operating metrics

STERIS Revenue Breakdown

Embed Graph

STERIS revenue breakdown by business segment: 27.4% from Capital equipment, 23.1% from Consumable and 49.5% from Service

STERIS Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

STERIS Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

STERIS Online and Social Media Presence

STERIS's Trends

Embed Graph

STERIS Company Culture

  • Overall Culture

    C+

    67/100

  • CEO Rating

    F

    48/100

  • Compensation

    C+

    66/100

Learn more on Comparably

STERIS News and Updates

February 03, 2021

STERIS Announces Leadership Succession Plan

DUBLIN, IRELAND, Feb. 03, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company’s Annual General Meeting. Mr. Rosebrough will r…
February 02, 2021

STERIS Announces Financial Results for Fiscal 2021 Third Quarter

DUBLIN, IRELAND , Feb. 02, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 third quarter ended December 31, 2020.  Revenue as reported for the quarter increased 4% to $808.9 million compared with $774.3 million in t…
January 12, 2021

Cantel Medical stock gains after agreement to be bought out by Steris, in a deal valued at $4.6 billion

Shares of Cantel Medical Corp. rose 1.8% in premarket trading Tuesday, after the infection prevention products company announced an agreement to be acquired by Ireland-based Steris PLC in a cash and equity deal valued at $4.6 billion, including debt. Steris shares fell 1.2%. Under terms of the dea…
January 12, 2021

STERIS Announces Definitive Agreement to Acquire Cantel Medical

DUBLIN, IRELAND and LITTLE FALLS, N.J, Jan. 12, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) and Cantel Medical Corp (NYSE:CMD) (“Cantel”) today announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary.  Cantel is a global …
January 12, 2021

The Wall Street Journal: Medical-supply companies Steris and Cantel in talks to join forces: sources

The coronavirus pandemic has been a mixed bag for the sterilization-products companies’ businesses.
January 07, 2021

STERIS To Participate in Upcoming Investor Conferences

DUBLIN, IRELAND, Jan. 07, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company will be publicly webcasting presentations made by Walt Rosebrough, President and Chief Executive Officer at two investor conferences next week.  The first presenta…
Show more

 STERIS Frequently Asked Questions

  • When was STERIS founded?

    STERIS was founded in 1987.

  • How many employees does STERIS have?

    STERIS has 12,000 employees.

  • What is STERIS revenue?

    Latest STERIS annual revenue is $2.6 b.

  • What is STERIS revenue per employee?

    Latest STERIS revenue per employee is $218.3 k.

  • Who are STERIS competitors?

    Competitors of STERIS include Sotera Health, Stryker and Cantel Medical.

  • Where is STERIS headquarters?

    STERIS headquarters is located at 5960 Heisley Rd, Mentor.

  • Where are STERIS offices?

    STERIS has offices in Mentor, Birmingham, Chester, Chesterfield and in 76 other locations.

  • How many offices does STERIS have?

    STERIS has 99 offices.